Pfizer and Astellas Pharma have shared positive top-line results from a late-stage study of their androgen receptor signalling inhibitor Xtandi (enzalutamide) in a subset of prostate cancer patients.

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...

CMS proposes the 2026 Physician Fee Schedule, addressing payment disparities in oncology, but warns of financial threats from ...

Corcept Therapeutics CORT announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of ...

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic ...

Psychological stress may increase the risk of cancer in BRCA mutation carriers. (British Journal of Cancer) Former Major League Baseball All-Star pitcher Bobby Jenks, 44, a member of the 2005 Chicago ...

Results from the Phase III EMBARK trial show that in combination with leuprolide, Xtandi (enzalutamide) demonstrated a ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...